Adjunctive treatment shows improved lesion control in intraocular tuberculoma, suggesting a new therapy approach.
Adjunctive intravitreal moxifloxacin and ranibizumab, when combined with systemic ATT and corticosteroids, appears to be a valuable therapeutic option in the management of intraocular tuberculoma, especially in cases with macular involvement. Tailored local therapy based on clinical phenotype may enhance lesion control and reduce systemic treatment duration.
No takes yet. Share an insight, caveat, or question.
Pant et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: